https://orcid.org/0000-0003-3758-8381
References
- HUMIRA® (adalimumab) injection, for subcutaneous use. Full prescribing information. North Chicago, IL: AbbVie Inc; 2019.
- TREMFYA® (guselkumab) injection, for subcutaneous use. Full prescribing information. Horsham, PA: Janssen Biotech, Inc; 2019.
- Enbrel® (etanercept) injection, for subcutaneous use. Full prescribing information. Thousand Oaks, CA: Amgen Inc; 2019.
- Aimovig® (erenumab-aooe) injection, for subcutaneous use. Full prescribing information. Thousand Oaks, CA: Amgen Inc; Novartis Pharmaceuticals Corporation, East Hanover, NJ; 2019.
- Keininger D, Coteur G. Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the Self-Injection Assessment Questionnaire (SIAQ). Health Qual Life Outcomes. 2011;9:2. doi:10.1186/1477-7525-9-2
- Makwana S, Basu B, Makasana Y, Dharamsi A. Prefilled syringes: an innovation in parenteral packaging. Int J Pharm Investig. 2011;1(4):200–206. doi:10.4103/2230-973X.93004
- Sauer M, Abbotts C. A new pen device for injection of recombinant human growth hormone: a convenience, functionality and usability evaluation study. Patient Prefer Adherence. 2018;12:27–34. doi:10.2147/PPA.S149412
- van den Bemt BJF, Gettings L, Domanska B, Bruggraber R, Mountian I, Kristensen LE. A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience. Drug Deliv. 2019;26(1):384–392. doi:10.1080/10717544.2019.1587043
- Lange J, Richard P, Bradley N. Usability of a new disposable autoinjector platform device: results of a formative study conducted with a broad user population. Med Devices. 2015;8:255–264. doi:10.2147/MDER.S85938
- Gandell DL, Bienen EJ, Gudeman J. Mode of injection and treatment adherence: results of a survey characterizing the perspectives of health care providers and US women 18–45 years old. Patient Prefer Adherence. 2019;13:351–361. doi:10.2147/PPA.S187120
- Aimovig (erenumab). Summary of product characteristics. Nuremberg, Germany: Novartis Pharma GmbH; 2019.
- Aimovig (erenumab-aooe) Product monograph. Dorval, Quebec: Novartis Pharmaceuticals Canada Inc; 2019.
- Dolgin E. First GPCR-directed antibody passes approval milestone. Nat Rev Drug Discov. 2018;17(7):457–459. doi:10.1038/nrd.2018.103
- Goadsby PJ, Reuter U, Hallstrom Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123–2132. doi:10.1056/NEJMoa1705848
- Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425–434. doi:10.1016/S1474-4422(17)30083-2
- Dodick DW, Ashina M, Brandes JL, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38(6):1026–1037. doi:10.1177/0333102418759786